ClearPoint Neuro, Inc. announced it has received 510(k) clearance for its Prism Bone Anchor Accessory. This clearance marks the Company?s second new product introduction within the first four months of 2024. The Prism Bone Anchor Accessory is intended to be used with commercially available stereotactic systems for intracranial and neurosurgical procedures which require accurate positioning of compatible small surgical instruments or accessories in the cranium, brain or nervous systems. It is designed to provide short-term fixation and positioning of compatible neurosurgical instruments or accessories under image-guidance.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.375 USD | +6.07% | +6.68% | -5.89% |
May. 07 | ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 07 | Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.89% | 165M | |
+12.94% | 227B | |
+13.77% | 192B | |
+18.11% | 136B | |
+28.25% | 108B | |
+1.67% | 64.07B | |
+17.80% | 52.1B | |
+7.04% | 51.87B | |
+10.62% | 44.33B | |
+5.96% | 36.75B |
- Stock Market
- Equities
- CLPT Stock
- News ClearPoint Neuro, Inc.
- ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory